Physiomics (GB:PYC) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Physiomics plc, a leader in mathematical modelling, has secured a £157k contract with a major pharmaceutical client to enhance dosing and scheduling decisions for a novel cancer therapy. This project marks the company’s first use of Antibody-Drug Conjugates in their Virtual Tumour platform, positioning Physiomics at the cutting edge of oncology drug development. The collaboration underscores the ongoing trust in Physiomics’ expertise in advanced therapeutic modelling.
For further insights into GB:PYC stock, check out TipRanks’ Stock Analysis page.
